Mouse prostate proteome changes induced by oral pentagalloylglucose treatment suggest targets for cancer chemoprevention

Current Cancer Drug Targets

Volumn 11, Issue 7, 2011, Pages 787-798

  Zhang, J ^a,c   Nkhata, K ^a   Shaik, A A ^a   Wang, L ^a   Li, L ^a,c   Zhang, Y ^a,c   Higgins, L A ^a   Kim, K H ^a   Liao, J D ^a   Xing, C ^a   Kim, S H ^a,b   Lu J ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Kyung Hee University   (South Korea)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer chemoprevention; ITRAQ; Penta 1, 2, 3, 4, 6 O galloyl beta D glucose (PGG); Prostate; Proteomic; Tolerated dose determination

Indexed keywords

ACTIN; CLUSTERIN; FATTY ACID SYNTHASE; GLUCOSE PENTAGALLATE; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE TRANSFERASE; ONCOPROTEIN; PROTEOME; REAGENT; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DENATURATION; RISK REDUCTION; TARGET ORGAN; THYMUS; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BODY WEIGHT; HYDROLYZABLE TANNINS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C57BL; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; PROTEOME; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80051721584     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796798959     Document Type: Article

References (23)

1. Zhang, J.; Li, L.; Kim, S. H.; Hagerman, A. E.; Lu, J. Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm. Res. 2009, 26 (9), 2066-2080.
2. Hu, H.; Lee, H. J.; Jiang, C.; Zhang, J.; Wang, L.; Zhao, Y.; Xiang, Q.; Lee, E. O.; Kim, S. H.; Lu, J. Penta-1,2,3,4,6-O-galloyl-beta-Dglucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo. Mol. Cancer Ther. 2008, 7 (9), 2681-2691.
3. Kuo, P. T.; Lin, T. P.; Liu, L. C.; Huang, C. H.; Lin, J. K.; Kao, J. Y.; Way, T. D. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGFinduced MMP-9 expression. J. Agri. Food Chem. 2009, 57 (8), 3331-3339.
4. Huh, J. E.; Lee, E. O.; Kim, M. S.; Kang, K. S.; Kim, C. H.; Cha, B. C.; Surh, Y. J.; Kim, S. H. Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis 2005, 26 (8), 1436-1445.
5. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3 (12), 1154-1169.
6. Chai, Y.; Lee, H. J.; Shaik, A. A.; Nkhata, K.; Xing, C.; Zhang, J.; Jeong, S. J.; Kim, S. H.; Lu, J. Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth. Breast Cancer Res. 2010, 12 (5), R67.
7. Li, L.; Shaik, A. A.; Zhang, J.; Nhkata, K.; Wang, L.; Zhang, Y.; Xing, C.; Kim, S. H.; Lu, J. Preparation of penta-O-galloyl-beta-Dglucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. J. Pharm. Biomed. Anal. 2011, 54 (3), 545-550.
8. Nishizawa, M.; Yamagishi, T.; Nonaka, G.; Nishioka, I.; Nagasawa, T.; Oura, H. Tannins and related compounds. XII. Isolation and characterization of galloylglucoses from Paeoniae Radix and their effects on urea-nitrogen concentration in rat serum. Chem. Pharm. Bull. 1983, 31 (8), 2593-2600.
9. Zhang, J.; Wang, L.; Anderson, L. B.; Witthuhn, B.; Xu, Y.; Lu, J. Proteomic profiling of potential molecular targets of methylselenium compounds in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev. Res. (Phila Pa) 2010, 3 (8), 994-1006.
10. Akkina, S. K.; Zhang, Y.; Nelsestuen, G. L.; Oetting, W. S.; Ibrahlm, H. N. Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition? J. Proteome Res. 2009, 8 (1), 94-103.
11. Shilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 2007, 6 (9), 1638-1655.
12. Zhang, J.; Wright, W.; Bernlohr, D. A.; Cushman, S. W.; Chen, X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am. J. Physiol. 2007, 292 (5), E1433-E1440.
13. Kassie, F.; Anderson, L. B.; Higgins, L.; Pan, Y.; Matise, I.; Negia, M.; Upadhyaya, P.; Wang, M.; Hecht, S. S. Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice. Carcinogenesis 2008, 29 (3), 610-619.
14. Birckbichler, P. J.; Bonner, R. B.; Hurst, R. E.; Bane, B. L.; Pitha, J. V.; Hemstreet, G. P. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 2000, 89 (2), 412-423.
15. Migita, T.; Ruiz, S.; Fornari, A.; Fiorentino, M.; Priolo, C.; Zadra, G.; Inazuka, F.; Grisanzio, C.; Palescandolo, E.; Shin, E.; Fiore, C.; Xie, W.; Kung, A. L.; Febbo, P. G.; Subramanian, A.; Mucci, L.; Ma, J.; Signoretti, S.; Stampfer, M.; Hahn, W. C.; Finn, S.; Loda, M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl. Cancer Inst. 2009, 101 (7), 519-532.
16. Sivonova, M.; Waczulikova, I.; Dobrota, D.; Matakova, T.; Hatok, J.; Racay, P.; Kliment, J. Polymorphisms of glutathione-Stransferase M1, T1, P1 and the risk of prostate cancer: a casecontrol study. J. Exp. Clin. Cancer Res. 2009, 28 (1), 32.
17. Chi, K. N.; Zoubeidi, A.; Gleave, M. E. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin. Invest. Drugs 2008, 17 (12), 1955-1962.
18. Feldman, K. S.; Sahasrabudhe, K.; Smith, R. S.; Scheuchenzuber, W. J. Immunostimulation by plant polyphenols: a relationship between tumor necrosis factor-alpha production and tannin structure. Bioorg. Med. Chem. Lett. 1999, 9 (7), 985-990.
19. Garbis, S. D.; Tyritzis, S. I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E. G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; Pavlakis, K.; Sanoudou, D.; Constantinides, C. A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 2008, 7 (8), 3146-3158.
20. Ayala, G.; Tuxhorn, J. A.; Wheeler, T. M.; Frolov, A.; Scardino, P. T.; Ohori, M.; Wheeler, M.; Spitler, J.; Rowley, D. R. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 2003, 9 (13), 4792-4801.
21. Assinder, S. J.; Stanton, J. A.; Prasad, P. D., Transgelin: an actinbinding protein and tumour suppressor. Int. J. Biochem. Cell Biol. 2009, 41 (3), 482-486.
22. Setiady, Y. Y.; Ohno, K.; Samy, E. T.; Bagavant, H.; Qiao, H.; Sharp, C.; She, J. X.; Tung, K. S. Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells. Blood 2006, 107 (3), 1056-1062.
23. Fujimoto, N.; Akimoto, Y.; Suzuki, T.; Kitamura, S.; Ohta, S. Identification of prostatic-secreted proteins in mice by mass spectrometric analysis and evaluation of lobe-specific and androgen-dependent mRNA expression. J. Endocrinol. 2006, 190 (3), 793-803.